Other
Anti-PD-1 Antibody
0
Pipeline Programs↗
6
Active Trials↗
0
Companies Involved↗
Anti-PD-1 Antibody is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
20
clinical trials
Unknown status8 · 40%
Recruiting3 · 15%
Not yet recruiting3 · 15%
Completed3 · 15%
Withdrawn2 · 10%
Terminated1 · 5%
Clinical Trials
Trial Activity
20 trials
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Recruiting·—·Phase 2·NCT06393361·100 enrolled
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Not yet recruiting·—·Phase 2·NCT06563778·100 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)